← Leaderboards
Jianjian Shi
Indiana University Indianapolis
$1,079,465
Attributed
$2,158,929
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $659.3K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,158,929 · 2
By mechanism
R01$1,755,090 · 1
R21$403,839 · 1
Top collaborators
- Lei Wei4 shared
- Reuben Kapur2 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Lei Wei$10,679,581
- Reuben Kapur$21,257,649
- Anthony B. Firulli$18,318,152
- Matthew D. Durbin$1,888,794
- Benjamin M Sivyer$4,300,195
Others in their field
Other Emerging Leaders on “Smooth Muscle Myocytes”
- Jesse M Engreitz · Stanford University$5,564,865
- Matthew A Nystoriak · University Of Louisville$4,288,754
- Yen Chun Charly Lai · Indiana University Indianapolis$4,180,151
- Yanbo Fan · University Of Cincinnati$4,173,519
- Delphine Gomez · University Of Pittsburgh At Pittsburgh$3,973,818
- Sal Baker · University Of Nevada Reno$3,944,680
Research focus
Smooth Muscle MyocytesHuman ModelMediatingSignal PathwayRho-Associated KinaseMolecularFasudilKnockout MicePhosphotransferasesRock1 GeneStressCardiac MyocytesCardiacOutcome StudyAutophagocytosisCell TypeHeart FunctionCytoskeletonActinsEtiologyComplexAdultCoronary FibrosisExperimental Study
Grant awards (6)
Role of ROCK isoform-mediated actin cytoskeleton modification in the pathogenesis of heart disease$436,060
R01 · FY2024 · HL
Role of ROCK isoform-mediated actin cytoskeleton modification in the pathogenesis of heart disease$444,960
R01 · FY2023 · HL
Dual anti-leukemic and cardio protective role for ROCK$181,543
R21 · FY2023 · CA
Role of ROCK isoform-mediated actin cytoskeleton modification in the pathogenesis of heart disease$437,035
R01 · FY2022 · HL
Dual anti-leukemic and cardio protective role for ROCK$222,296
R21 · FY2022 · CA
Role of ROCK isoform-mediated actin cytoskeleton modification in the pathogenesis of heart disease$437,035
R01 · FY2021 · HL